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The use of artificial tissues in regenerative medicine is limited due to hypoxia. As a strategy to overcome
this drawback, we have shown that photosynthetic biomaterials can produce and provide oxygen
independently of blood perfusion by generating chimeric animal-plant tissues during dermal regener-
ation. In this work, we demonstrate the safety and efficacy of photosynthetic biomaterials in vivo after
engraftment in a fully immunocompetent mouse skin defect model. Further, we show that it is also
possible to genetically engineer such photosynthetic scaffolds to deliver other key molecules in addition
to oxygen. As a proof-of-concept, biomaterials were loaded with gene modified microalgae expressing
the angiogenic recombinant protein VEGF. Survival of the algae, growth factor delivery and regenerative
potential were evaluated in vitro and in vivo. This work proposes the use of photosynthetic gene therapy
in regenerative medicine and provides scientific evidence for the use of engineered microalgae as an
alternative to deliver recombinant molecules for gene therapy.
© 2015 Elsevier Ltd. All rights reserved.1. Introduction
Oxygen is an essential molecule for cell metabolism. It plays a
key role in tissue survival and regeneration, yet paradoxically, its
appropriate delivery is one of the major problems for the clinical
translation of non-vascularized tissue engineering approaches [1].
As a result, cells within bioartificial tissue constructs are stringentlyd Hand Surgery, University
en, Ismaningerstr. 22, 81675dependent on oxygen diffusion, which barely reaches few hundred
micrometers and limits the construction of artificial tissues to non-
clinically relevant sizes [2]. Besides the basic oxygen requirements,
tissue regeneration relies on several bioactive molecules, such as
growth factors, that control key processes including inflammation,
angiogenesis and tissue remodeling [3e5]. Scaffold bioactivation
with growth factors has been intensively investigated as strategy to
enhance the regenerative potential of engineered tissues [6].
However, direct growth factor administration has major limitations
related to the short biological half-life of the molecules, and the
consequent need for repeated administration of large and poten-
tially toxic bulk doses [7,8]. Conversely, traditional gene therapy
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supply. Yet, this approach raises ethical and technical concerns that
affect their translation into clinical settings. For instance, the de-
livery of target genes often creates risk of oncogenicity, insertional
mutagenesis and viral vector-related immune reactions [9,10],
while target tissue-specificity and high transduction efficiency are
still unrealized for non-viral gene delivery methods [11,12]. Addi-
tionally, sustained transgene expression is not guaranteed if the
transgenic cell survival depends of local oxygen tension at the in-
jection site.
Recently, we have introduced HULK (from the German Hyper-
oxie Unter Licht Konditionierung) as a novel concept to deliver ox-
ygen into biomaterials independently of blood vessel perfusion.
The main idea behind the HULK approach is that, by incorporating
photosynthetic microalgae such as Chlamydomonas reinhardtii
(C. reinhardtii) into artificial constructs, the local induction of
photosynthesis could be able to supply the metabolic needs of
bioengineered tissues in vitro [13] and in vivo [14]. To take HULK
one step forward, in this work we evaluated the feasibility of
implanting photosynthetic scaffolds in fully immunocompetent
mice. Then, we explored the idea of using genetically modified
microalgae to engineer photosynthetic scaffolds that, in addition to
oxygen, could provide other pro-regenerative molecules to the
wounded tissue. As a proof of concept, we created a gene modified
C. reinhardtii strain that constitutively secretes the human vascular
endothelial growth factor VEGF-165 (VEGF).
In this work we propose that the activation of biomaterials with
gene modified microalgae could be used to locally deliver oxygen
and other pro-regenerative molecules into bioartificial tissue
constructs.
2. Materials and methods
2.1. Cell culture of C. reinhardtii
The cell-wall deficient, cw15-30-derived UVM4 C. reinhardtii
strain [15] was grown photomixotrophically at 20 C on either solid
Tris Acetate Phosphate (TAP) medium or in liquid TAPS-medium
supplemented with 1% (w/v) sorbitol [16]. For light stimulation, a
lamp with the full spectrum of white light (Nano Light, 11 Watt,
Dennerle, Vinningen, Germany) was used to provide constant
illumination (2500 lux, eq. 72.5 mE/m2∙s1). Cell concentration in the
culture was determined using a Casy Counter TT (Roche Di-
agnostics, Mannheim, Germany).
2.2. Cell seeding in the scaffolds
For in vitro experiments, if not stated otherwise, Integra®matrix
single layer (Integra Life Science Corporation, Plainsboro, NJ, USA)
was used as a scaffold. For seeding, a C. reinhardtii, suspension was
mixed with fibrinogen (Tissucol-Kit 2.0 Immuno, Baxter GmbH,
Unterschleibheim, Germany) in a 1:1 ratio to the respective final
concentration. Pieces of IM (ø 12 mm,1 mm thick) were cut using a
biopsy punch and dried with sterile gauze. 50 ml thrombin-solution
(Tissucol-Kit 2.0 Immuno, Baxter GmbH, Unterschleibheim, Ger-
many) followed by 100 ml of the algae-fibrinogen solution were
pipetted over each scaffold. Control scaffolds were prepared by
adding 50 ml thrombin and 100 ml TAPS-fibrinogen 1:1 solution.
After 1 h, the scaffolds were covered with TAPS-buffer and incu-
bated over the desired period of time at room temperature and
constant illumination. Pictures of the scaffolds at different time
points were taken with a stereomicroscope (Stereomicroscope
Stemi 2000-C, Carl Zeiss AG, Oberkochen, Germany) or an inverted
phase-contrast microscope (Axiovert 25, Carl Zeiss AG, Oberko-
chen, Germany) and analyzed with the Axiovision software (CarlZeiss AG, Oberkochen, Germany).2.3. Construction of transformation vector
The coding sequence for the human vascular endothelial growth
factor A isoform l (accession number NP_001165097) was adapted
to the codon bias of C. reinhardtii. The synthetic gene pBC1-
VEGF165 was assembled from synthetic oligonucleotides and
PCR-products. The sequence was inserted into an expression
cassette derived from the endogenous PsaD gene 50 and 30 UTRs
regulatory elements and behind the export sequence encoding the
21 amino acid leader peptide of the C. reinhardtii extracellular
enzyme arylsulfatase (ARS2) to target the transgenic proteins for
secretion into the culture medium. The pBC1-CrGFP_J131 basis
vector [15] contained the APHVIII resistance gene for selection on
paromomycin, whose expression is controlled by the constitutively
active HSP70/RBCS2 promoter regions and the first intron of the
RBCS2 gene. The transgene fragment was cloned into the vector
backbone pBC1-CrGFP_J131 using NdeI and EcoRI cloning sites. The
final constructs were verified by sequencing. The plasmid DNAwas
replicated and purified from transformed E. coli K12
(dam þ dcm þ tonA rec-) bacteria. All this was performed by Gene
Art AG, Life Technologies, Regensburg, Germany.2.4. Transformation of C. reinhardtii
1$107 UVM4 C. reinhardtii-cells were suspended to a volume of
300 ml and vortexed with ø 0.5 mm glass beads for 20 s in the
presence of 5 mg plasmid DNA. Then, the transformants were
seeded in TAPS-liquid medium and incubated overnight protected
from light under continuous shaking. Next, the algae were seeded
over TAP-Agar plates containing 10 mg/ml paromomycin and incu-
bated for the first three days under weak illumination. Upon suc-
cessful transformation, the new created strains integrated an
antibiotic-resistance gene and were therefore able to grow selec-
tively in the presence of paromomycin. The plates were thenmoved
to conditions with standard light exposition (2500 lux), until the
colonies were large enough to be picked and platted into a fresh
plate. Clones were subsequently maintained in solid TAP-medium
under selective conditions.2.5. Southern blot
Genomic DNA from C. reinhardtii cells was extracted using the
DNeasy Plant Mini Kit (Qiagen N.V., Lumburg, Netherlands) ac-
cording to the manufacturer's instructions. 10 mg DNA were diges-
ted using the restriction enzymes HindIII and BamHI at 37 C for
48 h. Samples were separated by 0.8% agarose-TBE gel electro-
phoresis for 16 h at 25 V. Following depurination (15 min, 0.25 M
HCl), denaturation (30 min, 0.4 M NaOH, 0.6 M NaCl) and
neutralization (30 min, 1 M TriseHCl pH 8.0, 1.5 M NaCl) genomic
DNA was transferred to a nylon membrane (Roti-Nylon plus,; Carl-
Roth, Karlsruhe, Germany) in 20 SCC (3 M NaCl, 0.3 M Triso-
diumcitrate) overnight. Digoxigenin-nucleotide labeled DNA-
probes (Digoxigenin-11-dUTP alkali-labile, Roche, Basel,
Switzerland) were obtained using the same primer pairs and con-
ditions as for the PCR (see below). After blocking unspecific binding
sites, immobilized genomic DNA was incubated with the labeled
probes for 14 h at 68 C for hybridization. Signals were detected
using an alkaline phosphatase conjugated anti-DIG antibody
(Roche, Basel, Switzerland) and CDP* (Roche, Basel, Switzerland) as
reaction substrate.
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The integration of the recombinant gene was confirmed by PCR
using the gene specific primer pair 50-GAAGTTCATGGACGTGTACC-
30 and 50-TTGTTGTGCTGCAGGAAG-30, 258 bp product. The primer
sequences for the amplification of the psbD sequence were 50-
GCCGTAGGGTTGAATG-30 and 50-GTTGGTGTCAACTTGGTGG-30,
413 bp product (Metabion GmbH, Planegg/Steinkirchen, Germany).
2.7. Western blot
Total soluble protein extracts were prepared by resuspending
5$107 pelleted C. reinhardtii cells (5 min, 10,000 rpm) in 100 ml lysis
buffer (100mM Tris-HCL,10mM EDTA, 0.5% Triton-X-100, 25 mg/ml
pepstatin, 25 mg/ml leupeptin, 25 mg/ml aprotinin). Cells were
disrupted and lysates were homogenized by pipetting up and down
through a 1 ml syringe and stored at 80 C for further analysis.
Equal protein amounts were denatured at 95 C for 5 min in the
presence of reducing loading buffer (0.03 M Tris pH 6.8, 10% SDS,
15% Glycerin, 0.03% bromphenolblue, 12.5% 2-mercaptoethanol),
separated by gel-electrophoresis and transferred to PVDF-
membranes. Commercially available human VEGF-165 was loaded
as a positive control (Preprotech, NJ, USA). Protein detection was
performed using a monoclonal rabbit anti-VEGF primary antibody
(1:1000 dilution, ab51917, Abcam, plc, Cambridge, UK) and rabbit
anti-HSP70 serum (kindly provided by Michael Schroda, Depart-
ment of Molecular Biotechnology and Systems Biology, TUK, Kai-
serslautern, Germany), and a goat anti-rabbit HRP secondary
antibody (1:5000, Dianova GmbH, Hamburg, Germany), using the
SuperSignal West Pico detection system (Pierce-Thermo Fisher
Scientific Inc, IL, USA).
2.8. Enzyme-linked ImmunoSorbent assay (ELISA)
5$107 C. reinhardtii cells were seeded in triplicate in 10 ml vol-
ume and incubated at room temperature for 4 days under constant
agitation (150 rpm) and illumination (2500 lux). Culture superna-
tants were collected and then stored at 80 C until their analysis.
Protein lysates from the explanted scaffolds were obtained by
mechanical disruption in RIPA buffer with proteinase inhibitors
(PIC; BD Pharmingen, NJ, USA), Pefabloc SC-Protease Inhibitor (Carl-
Roth, Karlsruhe, Germany), cOmplete (Roche, Basel, Switzerland),
phenylmethylsulfonyl fluoride (PMSF; SigmaeAldrich, MO, USA).
To assess the secretion of the recombinant proteins from the
encapsulated algae, scaffolds were seeded as described before with
transgenic algae at a final concentration of 0.5$106 cells per scaffold
and placed in 12 well-plates with 2 ml TAPS-medium. Mediumwas
changed every day and collected every two days. For quantification
of the secreted recombinant proteins in the supernatant samples
and lysates, the human VEGF Quantikine ELISA kit was used ac-
cording to the manufacturer's instructions. Here, a monoclonal
antibody raised against the Sf 21-expressed recombinant human
protein VEGF-165 was used as a capture antibody and a specific
polyclonal antibody as the detection antibody.
2.9. Recovery of the recombinant protein from the culture
supernatant
The supernatants from confluent C. reinhardtii cultures were
passed first through a 0.22 mm filter. Then using a filtration tube
capable of retaining peptides above 3000 Da (Vivaspin 15R
Hydrosart, Sarstedt, G€ottingen, Germany) VEGF-165 was recovered
by centrifugation (3000  g, 47 min). In a final filtration step, the
diluent medium was changed to cell starvation medium (RPMI
1640, with stable glutamine and 2.0 g/L NaHCO3; Biochrom, Berlin,Germany) supplemented with 1% fetal calf serum (FCS-Gold, PAA,
Pasching, Austria) and 1% antibiotic/antimycotic (100 ab/am;
Capricorn Scientific, Ebsdorfergrund, Germany).
2.10. Cell culture of human endothelial progenitor cells
Human umbilical vein endothelial cells (HUVECs) were either
purchased (Promocell, Heidelberg, Germany) or obtained from
umbilical cord donors as described before [17]. Cells were main-
tained in supplemented Endothelial Cell Growth Medium 2 (Pro-
mocell, Heidelberg, Germany) with 1% penicillin/streptomycin
(Biochrom, Berlin, Germany) under standard cell culture conditions
(37 C, 5% CO2). In all experimental settings, cells from passages
2e4 were used.
2.11. Receptor phosphorylation assay
HUVECs (1$105 cells per well) were seeded on a 12 well-plate,
cultured for 24 h and then starved for 16 h before activation.
Cells were then stimulated for 2 min, with either 50 ng/ml re-
combinant VEGF-165 (Preprotech, NJ, USA), or the concentrated
protein supernatants of 30 ml confluent cultures of the genetic
modified and wild-type strains (approx. 2$107 cells/ml). Cells were
then snap-frozen by submerging the plate in liquid nitrogen and
lysed in RIPA-buffer with proteinase inhibitors and phosphatase
inhibitors (Phosphatase Inhibitor Mini Tablets; Pierce-Thermo
Fisher Scientific Inc, IL, USA). Cells were scratched from the well-
floor and lysates were homogenized by pipetting up and down
through a 1 ml syringe, centrifuged for 5 min at 9300 g and stored
at 80 C for further analysis. Equal protein amounts were sepa-
rated by gel-electrophoresis under reducing conditions and then
blotted to PVDF-membranes (Bio-Rad Laboratories, Hercules, Cali-
fornia, USA). Themononuclear antibodies rabbit mAb anti-VEGFR-2
and rabbit mAb anti-phospho-VEGFR-2 (Tyr1175) (CellSignalling,
MA, USA) were used for the detection of the phosphorylated and
non-phosphorylated receptor epitope with overnight incubation
periods. Pixel intensity quantification was performed with the
software Fusion (Peqlab, Erlangen, Germany).
2.12. Cell proliferation assay
HUVECs (2$104 cells per well) were seeded in a 24-well plate.
Cells were grown into 60% confluence. Next, mediumwas replaced
by starvation medium overnight. Cells were then stimulated every
12 h for 48 h with either 50 ng/ml recombinant VEGF-165, the
concentrated protein supernatants of confluent cultures of the
genetically modified algae or wild-type strains. Then, cells were
trypsinized (Trypsin/EDTA 1, PAA, GE Healthcare, USA) and
counted using trypan blue (Trypan Blue solution; SigmaeAldrich,
MO, USA) as dead-staining. For immunohistological analysis, cells
were fixed in 3.5e3.7% formaldehyde (Otto Fischar GmbH und Co.
KG, Saarbrücken, Germany) by the end of the experimental time
and stained with a monoclonal rabbit anti-VEGF primary antibody
(1:1000, ab51917, Abcam, plc, Cambridge, UK) and a goat anti rabbit
secondary antibody (1:1000, Alexa 568, A11011,Thermo Fisher
Scientific, Waltham, USA).
2.13. Cell migration assay
HUVECs (1$104 cells per well) were seeded in 70 ml culture
medium into each well of a culture insert (Ibidi, Martinsried, Ger-
many). Cells were grown into confluence. Next, culture inserts were
removed and medium was replaced by starvation medium over-
night. Cells were then stimulated every for 24 h with either 50 ng/
ml recombinant VEGF-165 (positive control), the concentrated
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modified strain or the wild-type strain. Then, cells were stained
with calcein AM (Invitrogen, Oregon, USA), according to manufac-
turer's instructions, to visualize living cells. Microscopic pictures
were takenwith an Axio Observer Z1 microscope (Zeiss, G€ottingen,
Germany) and the number of migrating cells into the open wound
area was quantified with the software ImageJ [18].
2.14. Zebrafish breeding
Zebrafish (Danio rerio) embryos were obtained from the
laboratory-breeding colony. Embryos were collected by natural
spawning and raised at 28.5 C in E3 medium (5 mMNaCl, 0.17 mM
KCl, 0.33 mM CaCl2, 0.3 mM MgSO4 equilibrated to pH 7.0); egg
water was changed daily. Embryonic ages are expressed as days
post-fertilization (dpf). Animals were anesthetized with MS-222
(Tricaine, A5040, SigmaeAldrich, MO, USA) before each experi-
ment. All procedures complied with guidelines of the Animal Ethics
Committee of the University of Chile.
2.15. Zebrafish model of angiogenesis
Zebrafish (D. rerio) embryos of the transgenic strain
Tg(fli1a:EGFP)y1 [19] were collected and raised at 28.5 C in E3
medium. C. reinhardtii cells were brought to a concentration of
5$107 cells/ml in fresh TAPS-medium and loaded to glass capillary
needles. Previously selected and dechorionated transgenic zebra-
fish embryos of 1 dpf were injected with approximately 10 nl of the
respective cell suspension into the yolk sack. 20e30 zebrafish
larvae were injected per group. Embryos were incubated for 24 h in
E3 medium and for further 48 h in E3 with Phenylthiourea (PTU, N-
Phenylthiourea, SigmaeAldrich, MO, USA) at 28 C and imaged as
described below in this section.
2.16. Confocal microscopy, fluorescence microscopy and image
processing
Living zebrafish embryos were chosen randomly, anesthetized
and mounted in 0.75% low-melting point agarose containing 5%
Tricaine in a 35 mm imaging dish, and fixed to a lateral position.
Embryos were first examined using an epifluorescence-inverted
microscope (Olympus scan, Olympus Biosystems, Munich, Ger-
many). Z-stack images were taken at a fixed 15 mm intervals in a
confocal microscope (Zeiss LSM 510 Meta, Carl Zeiss AG, Oberko-
chen, Germany). Z-Projections of the stacks were then merged and
combined to generate a mosaic image of the whole fish using the
software Zeiss LSM Image Browser Version 3.1.0.99, ImageJ 1.46r
(Java 1.6.0_20 (64-bit)), the software ImageJ [18] and the plugin
MosaicJ [20].
2.17. Chlorophyll measurements
Scaffolds were seeded with 3$105 C. reinhardtii cells as described
in section 2.2. At different culture times (days 1, 7, 14) the scaffolds
were mechanically disrupted and optical density was measured at
435 nm (Nanodrop, Thermo Scientific, Waltham, MA, USA) as
described before [13].
2.18. Oxygen release measurements
Scaffolds were seeded at a final concentration of 2.5$106 cells
per scaffold and incubated for 5 days at room temperature, fol-
lowed by a 16 h dark time incubation period, prior to the start of the
measurement. Afterwards, samples were placed under hypoxic
conditions (1% pO2) and oxygen concentrations in vitro wereconstantly measured by the SensorDish® Reader (PreSens GmbH,
Regensburg, Germany) in Oxodish® well-plates according to the
manufacturer's instructions. For light stimulation, a lamp (Nano
Light, 11Watt, Dennerle, Vinningen, Germany) was placed at 40 cm
distance over the sample. Oxygen concentration was recorded over
24 h.2.19. Full-skin defect
For in vivo experiments, scaffolds were prepared as for the ox-
ygen release measurements, but in this case Integra® dermal
regeneration template (Integra Life Science Corporation, Plains-
boro, NJ, USA) was used. All procedures on laboratory animals were
approved by the District Government of Upper Bavaria (Regierung
von Oberbayern) and performed according to the current German
animal welfare act (TierSchG). Experiments were performed on
female Skh1 hairless mice (Crl:SKH1-Hrhr, Charles River, Sulzfeld,
Germany) of 6e8 weeks age and body weight of 20e25 g. Under
inhalative anesthesia (Isoflurane, Baxter Germany, Unters-
chleissheim, Germany) a bilateral 10 mm full skin defect was
created on the back of themice by first using a 10mmbiopsy punch
to delineate the excision areas, and then, using fine surgical scissors
to remove the skin. Next, a round piece of titanizedmesh (ø 13mm)
was placed over the wound bed and under the wound edges.
Control and microalgae-seeded scaffolds were placed over the
mesh and then sutured to the adjacent wound edges with 6e8
single knots, leaving the edges slightly over the scaffold. The
wounds were covered with a transparent dressing (V.A.C.® Drape,
KCI Medical Products, Wimborne Dorset, UK), which was also su-
tured to the skin. In order to trigger the oxygen production, cages
were equipped with a flexible LED module (20 V, 14.4 W, WW,
2700 K, Ledxon, Landshut, Germany) to stimulate the photosyn-
thetic scaffolds with additional 3500 Lux during daytime. Accord-
ing to the TierSchG, animalsmust be subjected to circadian cycles of
12/12 h light/darkness. Thus, photosynthetic implants could not be
exposed for more than 12 h to light stimulation per day. Control
animals were kept under the same light stimulation conditions. At
the end of the experimental times, animals were sacrificed via
isofluorane overdose and the skin from the back including the
scaffolds was excised for further analysis. To evaluate the systemic
effects of implanting photosynthetic biomaterial, weight loss of the
animals at the end of the experimental time was recorded. Further,
the immune organs, thymus, spleen, mesenteric (MLN), and iliac
lymph nodes (LN), were removed and their size and weight were
measured and related to their final body weight. Whole blood was
collected directly from the heart and allowed to clot by leaving it
undisturbed on ice for 1 h. The clot was removed by centrifugation
at 2000 g for 10 min at 4 C. Serum was transferred into clean test
tubes and stored at 80 C for further analysis. Three animals per
group were used in this study.2.20. Fluorescence-activated cell sorting (FACS)
Harvested organs were homogenized by mechanical disruption
and filtered through a 100 mm cell strainer. Following red blood cell
lysis treatment, 1$106 cells were stained for flow cytometry using
the following fluorochrome conjugated antibodies: anti-CD4 (RM4-
5, Ordering No: 12004183), anti-CD19 (1D3, Ordering No:
12019381), anti-CD69 (H1.2F3, Ordering No: 45069182), anti-CD44
(IM7, Ordering No: 11-0441-81) all from eBioscience (eBioscience,
Inc., CA, USA), and anti-CD8a (53-6.7, Ordering No: 553033) from
BD Pharmingen (BD Pharmingen, NJ, USA). Samples were acquired
using FACS CantoII (BD Biosciences, NJ, USA) and analyzed with
FlowJo software (Treestar, Or, USA).
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The concentration of inflammatory cytokines in serum was
determined by a BD™ CBA Mouse Inflammation Kit (BD Pharmin-
gen, NJ, USA) following the manufacturer's instructions. This assay
quantitatively measures IL-6, IL-10, IL-12p70, MCP-1, IFN-g, and
TNF protein levels in a single sample. Briefly, capture beads con-
jugated with a specific antibody and detector phycoerythrin (PE)-
conjugated antibodies are incubated with an unknown sample.
Then, sandwich complexes of capture bead, analyte and detection
reagent are formed, and provide a fluorescent signal which is
measured by flow cytometry. This signal is compared to a calibra-
tion curve obtained with recombinant cytokines in order to obtain
the amount of bound analyte.
2.22. Viability of the algae ex vivo
Biopsies of the explanted scaffolds of approximately
12 mm  1 mm were taken after 7 and 14 days post-implantation
(dpi). Then, they were incubated for 24 h in liquid TAPS medium
with 10 mg/ml paromomycin (SigmaeAldrich, MO, USA), centri-
fuged (290  g, 5 min) and cultured for two weeks in TAPS-agar
plates containing the same concentration of antibiotics.
2.23. Visualization and quantification of the vascular network
In order to quantify the rate of vascularization over the wound,
tissue transillumination and digital segmentation was performed
as described before [21]. Briefly, the skin from the back of the an-
imals was removed and stretched out on a petri dish over a
transilluminator device. Then, pictures of the growing vascular
network over the wound bed were taken using a stereomicroscope
(Stereomicroscope Stemi 2000-C, Carl Zeiss AG, Oberkochen, Ger-
many). A mask of the growing network under each scaffold and the
vasculature of the uninjured skin was drawn by hand and then
processed by the VesSeg-Tool analysis software [22]. For the anal-
ysis, the number and length of vessels and not their size was
regarded. Therefore, prior to the estimation of the area covered by
the microvasculature, all vessels were thinned to a width of one
pixel. Results were expressed as percentage of vascularized area
compared to normal skin.
2.24. Histology and immunohistochemistry
Sections (2 mm) of diverse organs and the explanted tissues
(fixed in 4% paraformaldehyde and paraffin-embedded) were
stained with Hematoxylin (Ordering No: 351945S, VWR Chemicals,
Radnor, PA, USA)/Eosin (1B-425, Waldeck GmbH& Co. KG, Münster,
Germany) or various antibodies. Incubation was performed with
Bond Polymer Refine Detection Kit (Ordering No: DS9800, Leica
Biosystems, Nussloch, Germany) on a Bond MAX (Leica). For
quantification of the stainings, slides were scanned using a SCN400
slide scanner (Leica Biosystems, Nussloch, Germany) and analyzed
using Tissue IA image analysis software (Slidepath, Leica Bio-
systems, Nussloch, Germany). Antibodies raised against the
following antigens were used for immunohistochemistry: CD31
(1:40; Ordering No: DIA310, Dianova GmbH, Hamburg, Germany),
aSMA (1:5000; Ordering No: A2547, SigmaeAldrich, MO, USA),
PDGFRb (1:50; Ordering No: 3169, CellSignalling, MA, USA), B220
(1:3000; Ordering No: 553084, BD Biosciences, NJ, USA), CD3
(1:250; Ordering No: RBK024, Zytomed, Berlin, Germany), F4/80
(1:120; Ordering No: T-2006, BMA Biomedicals AG, Augst
Switzerland), Ly6G (1:600; Ordering No: 551459, BD Pharmingen,
NJ, USA). Digital analysis and quantification of positively stained
cells were performed with the software ImageJ [18].2.25. Statistical analysis
All assays were repeated in at least 3 independent experiments.
If not stated otherwise, data was expressed as mean ± SD. Two-
tailed Student's t-test was used to compare differences between 2
groups. Differences among means were considered significant
when p  0.05.
3. Results
3.1. Engraftment of photosynthetic scaffolds does not trigger a
significant immune response
In our previous work, we showed that, after short periods of
implantation, the use of scaffolds seeded with the microalgae
C. reinhardtii, did not trigger a significant inflammatory response in
an athymic immunodeficient nude mice model [14]. Here, as a
further step to evaluate the safety of HULK in vivo, photosynthetic
scaffolds for dermal regeneration were used to replace full-skin
defects in fully immunocompetent mice [23] and the results were
evaluated after fourteen days. No complications were observed
during or after the surgical procedure, and no significant differ-
ences in weight were detected among the experimental groups
(Control 97.1% ± 5.5%, C.r. 103.8% ± 5.0%). Moreover, secondary
lymphoid organs (e.g. spleen, thymus, mesenteric and iliac lymph
nodes) did not show any significant increase in size nor signs of
inflammation (Fig. 1A, B). Histological analysis of these organs (e.g.
splenic white pulp follicles, B-cells follicles in MLNs) revealed
normal micro-architectural organization, cell composition and, did
not display any macroscopic or histological signs of possible im-
mune activation (Fig. 1C, Supplementary Fig. S1). Besides, we could
not detect any adverse effects in non-lymphoid organs (e.g. kidney,
liver, lung, pancreas (Supplementary Fig. S1), similarly suggesting
the lack of immune reaction. Furthermore, leukocyte activation did
not vary between the experimental and control groups (Fig.1D) and
no differences in the serum levels of inflammation-related cyto-
kines were detected (Fig. 1E). These results suggest that photo-
synthetic scaffolds can be implanted in an immunocompetent host
without causing a major inflammation or triggering a significant
immune response.
3.2. C. reinhardtii microalgae can be genetically modified to secrete
bioactive recombinant human growth factors
In order to go further in the development of autotrophic engi-
neered tissues, we next explored the idea of engineering bio-
materials that, in addition to oxygen, could locally deliver other
pro-regenerative molecules in situ. As a proof of concept, in this
work we created a genetically modified strain of C. reinhardtii,
capable to synthesize and secrete the angiogenic human growth
factor VEGF.
For genetic modification, the human sequence encoding for the
165 amino acid polypeptide chain of the growth factor VEGF-Awas
codon-adapted for its expression in C. reinhardtii (Supplementary
Fig. S2A). Upon transformation, the correct insertion of the trans-
gene was evaluated first by southern blot, which showed the
integration of a single copy of VEGF in the algae nuclear genome
(Supplementary Fig. 2B). Then, we confirmed the correct size of the
integrated human transgene using transgene-targeted PCR primers
(Fig. 2A). Western blot analysis, showed that the recombinant
growth factor had similar molecular weight as compared to a
commercially available recombinant human VEGF monomer
(Fig. 2B, 22.3 kD versus 19.2 kD), given that the recombinant pro-
tein synthesized by the microalgae was preceded by the 21 amino
acid export sequence of ARS2 (1.97 kD). The production of the
Fig. 1. Systemic inflammatory response in Skh-1 mice towards photosynthetic biomaterials. Two weeks after implantation of control scaffolds (Control) and scaffolds seeded
with algae (C.r.), no signs of inflammation in the lymphatic organs spleen, thymus, mesenteric lymph nodes (MLN) and iliac lymph nodes (ILN) were observed in neither control nor
experimental groups (A). The presence of the algae in the implant did not cause any significant increase in the size of the organs (B) and histological analysis of different inner
organs (C, spleen), showed a normal morphology and distribution of immune cells (B-cells (B220), T-cells (CD3), macrophages (F4-80), neutrophils (Ly6G). Fluorescence-activated
cell sorting analysis of splenic lymphocytes (CD4þ, CD8þ, and CD19þ) revealed similar CD44 and CD69 upregulation, suggesting comparable lymphocyte activation in both groups
(D). The inflammatory cytokines IL-6, IL-10, TNF, IFNg, and MCP-1 were present within a normal physiological range in the serum of animals in both groups (E). NS: non-significant.
N  3. Scale bar represents 0.5 cm in A and 100 mm in C.
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and showed a secretion rate of 1.4 ± 0.2 fg VEGF/cell (28.0 ± 4.38 ng
VEGF/ml) into the culture medium.
In order to evaluate the bioactivity of the recombinant VEGF,
in vitro and in vivo experiments were performed. First, human
primary endothelial cells were stimulated with culture medium
taken from modified algae. The ligand-binding induced auto-
phosphorylation of the VEGF-receptor 2 was confirmed by
western-blot (Fig. 2C, D). Moreover, the activation of the VEGF-
signaling pathway significantly increased the viability and migra-
tion capacity of the endothelial cells in vitro (Fig 2E, F). The bioac-
tivity of the gene modified algae was tested in vivo using zebrafish
larvae. For this, the microalgae were injected into the yolk sack of
the embryos at one day post-fertilization, and three days later
embryos were examined for morphological alterations in the
vasculature. Whereas mock-injected fish or fish injected with wild-
type algae did not show any alteration, an ingrowth of blood vessels
towards themodified algaewas evident in about 30% of the animals
(Fig. 3), proving the bioactivity of the modified algae in vivo. Such
vascular ingrowth was only observed when the majority of the
algae remained in a ventro-central position within the yolk sack.3.3. Photosynthetic scaffolds are able to release recombinant
growth factors, in addition to oxygen, and promote tissue
regeneration
In a next step, gene modified algae were seeded in clinically
available scaffolds for dermal regeneration and the sustained
release of photosynthetic oxygen and recombinant VEGF was
evaluated in vitro. Similar to what we have previously described
[14], when seeded at low concentrations, modified C. reinhardtii
cells were able to proliferate within the biomaterial (Fig. 4A, B) and
released substantial amounts of oxygen immediately upon light
stimulation, reaching the saturation limit of the oxygen sensor after
about 4 h (pO2  50%; 18.0 mg/L). In contrast, oxygen concentra-
tions of non-photosynthetic control scaffolds steadily declined over
the time (Fig. 4C). In addition, scaffolds seeded with gene modified
algae sustained a constant release of recombinant VEGF for at least
fourteen days in vitro (Fig. 4D). An average of 7.46 ± 1.66 ng VEGF/
ml was determined in the plateau of the secretion curve.
Finally, we studied the efficacy for the use of photosynthetic
scaffolds in a dermal regeneration model in vivo, and evaluated
their effects on the regeneration process and their capacity to
Fig. 2. Bioactivity of recombinant human VEGF expressed by C. reinhardtii in vitro. The correct insertion of the codon adapted human VEGF within the genome of the algae was
verified by PCR using primers specific for the transgene (GM). A non-transformed wild-type strain (WT) and a strain, which was genetically modified using the same vector (GFP),
were used as negative controls. The algal psbD gene was amplified as a control (A). Recombinant algal VEGF had a similar molecular weight as compared to the commercially
available recombinant protein (Control). The protein HSP70 was detected as a loading control (B). VEGF was secreted into the culture medium by gene-modified algae and a
concentrate of the culture supernatant was used to activate human endothelial cells. As a positive control, cells were stimulated with commercially available recombinant VEGF.
Binding of the growth factor to VEGFR-2 induced its phosphorylation (pVEGFR-2, C, D). Activation of the endothelial cells with algae-expressed VEGF supported their viability,
endothelial morphology and proliferative capacity (E) and increased their migration potential into a denuded area (F, dotted line). Scale bar represents 50 mm in E, and 200 mm in F.
N  3, *p < 0.05, **p < 0.005. Results are shown as mean ± SEM in E and as mean ± S.D in all other experiments.
Fig. 3. Bioactivity of recombinant human VEGF expressed by C. reinhardtii in vivo. Microalgae (red; chlorophyll auto fluorescence) were injected at 24 hpf into the yolk sack of
transgenic zebrafish embryos expressing EGFP in endothelial cells. Three days after injection, vessels grew towards the injected algae expressing VEGF. This alteration in the vessel
morphology was not observed in fish injected with wild-type algae or control injections. Z-projections of the fish and the yolk area are shown. Scale bar 150 mm. N  30. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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mice were compared: Control (non-seeded scaffolds), photosyn-
thetic scaffolds (seeded with wild-type algae) and gene modified
photosynthetic scaffolds (seeded with transgenic algae). Seven and
fourteen days after engraftment, the general outcome of the scaf-
folds was macroscopically evaluated and no signs of local infection,inflammation, rejection or necrosis were observed in the sur-
rounding wound area or within the engrafted scaffolds in either
group. Additionally, no significant wound contractionwas observed
and the defect remained similar in size in all three groups (Fig. 5A).
In order to determine the capacity of the modified algae to deliver
the desired recombinant proteins in vivo, the amount of human
Fig. 4. Gene modified microalgae seeded into photosynthetic dermal scaffolds. Encapsulated transgenic algae proliferated in the scaffold increasing the green color of the
scaffold (A) and its chlorophyll content as measured by light absorbance (B) over time. In contrast to control scaffolds, scaffolds seeded with transgenic algae (GM) raised the oxygen
concentration of the medium and reached the upper limit of detection (black arrow) upon light exposure under hypoxic conditions (C, pO2  1%). Non-cumulative quantification of
the growth factor release by encapsulated C. reinhardtii inside the scaffold is also shown (D). N  3. *p < 0.05, **p < 0.005. Scale bar represents 2.5 mm in A-top and 50 mm in A-
bottom. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 5. Photosynthetic gene therapy in vivo. Control scaffolds and scaffolds seeded with wild-type algae (WT) or gene-modified algae (GM) were engrafted in the back of Skh1-
mice for seven and fourteen days (A). Algal colonies were able to grow from biopsies of the scaffolds taken after 7 dpi, but not after 14 dpi (B). ELISA-analysis of the lysates of the
scaffolds detected the recombinant growth factor in the lysates obtained from the explanted scaffolds at both times (C). Quantification of mouse-VEGF showed increased levels of
the endogenous factor in both groups with photosynthetic scaffolds after 14 dpi (D). N  6. *p < 0.05. Scale bar represents 2.5 mm in A and 1 cm in B.
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transplantation. Although, the recombinant molecule was detected
at both experimental times, it was significantly lower at day four-
teen (Fig. 5C). This decrease in the concentration was consistent
with the survival curve of the algae in the wound, which was
corroborated by the capacity of transgenic algae to regrow from
biopsies of the explanted scaffolds after seven but not fourteen days
post-implantation (Fig. 5B). Interestingly, after fourteen days, the
sole presence of the algae promoted a significant increase of the
endogenous mouse VEGF in both photosynthetic groups compared
to the control (Fig. 5D).
After harvesting, implanted materials showed an ingrowth of
vasculature from the wound edge towards the wound bed and
below all three different implants (Fig. 6A). Unexpectedly, thepresence of genemodified algae in the wound had only mild effects
in promoting blood vessel formation, as seen after one week by an
increased number of CD31þ cells in the wound (Fig. 6C, D). Yet, by
day fourteen, the presence of the recombinant human VEGF did not
significantly increase the vascularization rate of the scaffold
(Fig. 6B). On the other hand, the implantation of photosynthetic
scaffolds, seeded either with wild-type or transgenic algae, signif-
icantly enhanced the recruitment of endothelial cells (CD31 posi-
tive cells, Fig. 6C, D) and the formation of alpha smooth actin
(aSMA) positive vessels in the wound bed area after fourteen days
(Fig. 6E, F). Furthermore, photosynthetic scaffolds remarkably
stimulated the formation of an extended granular-like tissue layer
underneath, which covered the entire defect after fourteen days
(Fig. 7A, C). When compared to the control scaffolds, this tissue
Fig. 6. Re-vascularization analysis of the wound area upon implantation of photosynthetic scaffolds. Transillumination pictures of harvested tissues were taken after 7 and 14
dpi using a stereomicroscope. Representative pictures are shown (A). The growing vascularization of the wound area was quantified by digital segmentation and related to normal
skin tissue at each time point (B). Image analysis of histological revealed an increased number of CD31 (C) and aSMA (E) positive cells in the photosynthetic tissues, in particular
within the regenerating tissue growing underneath the scaffolds after 14 dpi (D, F). Inserts show higher magnifications of the wound bed (dotted line) delimited by the titan-mesh
placed below the scaffold (*). N  6 * p < 0.05. Scale bar represents 2.5 mm in A, and 100 mm in C and E.
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dermis of the wound edge and was significantly thicker at both the
wound bed and below the wound edge (Fig. 7B, D). Additionally, it
was more densely populated with cells and a more pronounced
extension of the epidermis over the wound edge was observed in
both photosynthetic scaffolds, when compared to the control group
(Fig. 7C). Interestingly, a higher rate of matrix degradation was
observed in the photosynthetic scaffolds as judged by the loss of
the scaffold's original structure at day fourteen (Fig. 7A), and the
brittleness of the photosynthetic scaffolds noticed during the
preparation of the histological samples (data not shown).
4. Discussion
We previously proposed that the development of a photosyn-
thetic biomaterial, capable of oxygen self-production, could offer an
unlimited local source of oxygen supply for the regenerating tissue,
which would merely depend on light stimulation [13]. In this
approach, the green unicellular microalgae C. reinhardtii are
incorporated into scaffolds and exposed to illumination to trigger
photosynthesis and achieve oxygen production in situ. Moreover,
we also demonstrated that C. reinhardtii microalgae did not induce
a significant inflammatory response in two different species [14].
However, those previous results mainly evaluated the interaction of
the innate immune systemwith the algae. In order to further asses
the biocompatibility of the photosynthetic biomaterials, in this
study, photosynthetic scaffolds for dermal regeneration wereengrafted in the back of fully immunocompetent mice. Under this
new experimental setting, no overt immune response was
observed in the host organism (Fig. 1), and in agreement with our
previous study [14], these results further support the safety of the
HULK-approach within the context of tissue engineering.
In a further step towards the development of fully autotrophic
tissues, we made use of genetic manipulation tools to engineer a
scaffold that, in addition to oxygen, would be able to provide other
therapeutic molecules. Since re-establishment of a functional
vascular network is believed to be key for successful wound repair
[24,25], in this workwe decided to release the human growth factor
VEGF to introduce the concept of photosynthetic gene therapy.
Compared to other eukaryotic cells, the use of microalgae as a
vehicle could have an important impact on gene therapy, primarily
because their survival does not depend on external oxygen supply.
Besides, in this approach human transgenes are expressed from the
algal genome, which translates into no risk of insertional muta-
genesis, or potential oncogenicity for the human host. In this re-
gard, C. reinhardtii represents an attractive organism for
recombinant protein expression, because it combines the fast and
easy growth of unicellular microorganisms, with the advantages of
eukaryotic protein expression. Particularly, transgene expression
from the nuclear genome bids to direct proteins to organelles of the
secretory pathway, thus enabling post-translational modifications
and their final targeting for excretion [26], in contrast to chloroplast
expression [27]. Hence, today the list of recombinant proteins
successfully expressed by C. reinhardtii includes stable active
Fig. 7. Histological analysis of the implanted photosynthetic tissues and regenerating wound area. HE-staining of transversal scaffold-sections showed a granulation-tissue like
layer growing underneath the wound bed (A, dotted line) delimited by the titan-mesh placed under the scaffold (A, *). Inserts show higher magnifications of the scaffold (A, top left)
and wound bed (A, bottom right). The granulation-tissue like layer was significantly thinner and less dense with cells at the wound bed (B) and wound edge (D) for the control
scaffolds after 14 dpi. IHC-staining against PDRGF-R showed a more compact architecture of the connective tissue at the wound edge between the implant and the skin (B, dotted
line), and a more pronounced extension of the epidermis (B, black arrow head) in the photosynthetic scaffolds than in the control scaffolds. This suggests a robust bond between the
regenerating tissue and the adjacent dermis. Schematic views of the section and the measured area are shown (E: epidermis, D: dermis, S: scaffold, WB: wound bed). N  6,
*p < 0.05. Scale bar represents 100 mm.
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human growth factors [28].
The recombinant growth factor secretion by C. reinhardtii into
the culture medium, was found within the range of VEGF concen-
trations that are known to stimulate angiogenesis in vitro, and have
been previously used in other tissue engineered approaches
[29,30], although the expression rates of the algae are lower to
those accomplished using retrovirally transfected murine myo-
blasts [31,32]. Nevertheless, the stimulation of human cells with the
recombinant growth factor induced the autophosphorylation of the
VEGFR-2 receptor and had direct consequences in endothelial cell
survival, migration and proliferation in vitro (Fig. 2CeF). Further,
the injection of the transgene algae into zebrafish (Fig. 3), induced
similar alterations on the developing vascular architecture to those
described upon injection of other angiogenic molecules or angio-
genesis promoting cells [33e35]. Based on these results we
conclude that C. reinhardtii microalgae are capable to synthesize
and secrete functional pro-angiogenic growth factors in physio-
logically relevant amounts.
When seeded in a dermal scaffold, the transgenic algae sus-
tained a constant release of both oxygen and growth factors for
prolonged periods of time (Fig. 4C, D). As shown before [14], the
biocompatible fibrin encapsulation of C. reinhardtii grants a ho-
mogeneous confinement of the algae inside the scaffolds and at the
same time, allows the diffusion of oxygen produced by the prolif-
erating algae through the scaffold (Fig. 4 A, B). In this study, we
were also able to show a similar release of VEGF, and the averaged
growth factor concentration was found in the range of previously
described tissue engineering approaches [36e38]. Yet, in contrast
to the release kinetics of some of them, there is no peak of
expression or an early secretion burst. The expression curve of the
photosynthetic scaffolds rather follows the growth curve of the
seeded algae, resulting in a constant growth factor secretionsustained for as long as the algae are able to survive within the
scaffold (Fig. 4D).
Upon engraftment, the recombinant VEGF was found in the
protein lysates obtained from the explanted scaffolds after seven
and fourteen days post-implantation (Fig. 5C). Since the efficient
release of the recombinant growth factor from the biomaterial was
demonstrated in vitro (Fig. 4D), we conclude that the transgenic
algae were also able to synthesize VEGF in vivo, raising the con-
centration of the therapeutic molecule significantly in the wound
area inside the implant. This demonstrates that genetically engi-
neered C. reinhardtii could be used as an alternative method of
growth factor delivery for tissue engineering purposes.
However, there was a significant net decrease on the measured
concentrations of the growth factor after two weeks post-
implantation. In this work, we showed that the algae remained
alive and were able to regrow ex vivo after seven days of being
implanted in the host, yet the viability of the algae seemed to
terminate soon after this period of time (Fig. 5B). We therefore
concluded that the amount of recombinant growth factor is in
direct correlation with the number of viable microalgae in the
photosynthetic biomaterial. This could represent an advantage in
wound healing approaches, where transient delivery is desired.
However, for other long-term applications, the use of different
algae species with higher viability potential, or preconditioning
strategies such as temperature [40] and lightedark cycles [41]
could be explored to increase the viability of the algae in vivo.
Moreover, conditions upon implantation could be further opti-
mized. For instance, in the setting presented here, due to ethical
concerns, scaffolds were exposed to only 12 h of light per day,
which most probably affected key features such as survival and
metabolic rates of the algae.
While the recombinant VEGF promoted endothelial cell migra-
tion and blood vessel formation after one week, the presence of the
M.N. Chavez et al. / Biomaterials 75 (2016) 25e36 35transgenic algae did not significantly increase the rate of vascu-
larization over the wound bed afterwards (Fig. 6AeD). On this
subject, it is has been demonstrated and described that the for-
mation and maturation of functional blood vessels requires the
coordinated action of additional soluble factors such as FGF, TGFb,
PDGFB, Ang1, and PlGF [42e44]. Furthermore, it is known that
timing is crucial in the orchestration of a complex process, such as
wound re-vascularization. Although pro-angiogenic paracrine sig-
nals are present from day one after injury, the highest rate of
angiogenesis takes place between days 7e14 post-injury, following
a peak in wound hypoxia at day 4 [45,46]. If compared with the
viability of the algae in vivo, recombinant VEGF expression is not
matching the requirements of the regenerating tissue and the
availability of the growth factor decreases just when angiogenesis
is starting.
In spite of this, the implantation of the photosynthetic scaffolds
had two remarkable effects. First, a significant up-regulation of the
endogenous mouse VEGF expression was found in the lysates ob-
tained from the explanted photosynthetic scaffolds after twoweeks
post-implantation (Fig. 5D) and, as a most likely consequence,
already the presence of the wild-type photosynthetic algae in the
scaffold promoted the recruitment of endothelial progenitors
(CD31 positive cells) and the formations of alpha smooth actin
(aSMA) positive vessels in the wound bed area (Fig. 6CeF). In this
regard, HBO-therapy has shown to increase angiogenesis in hyp-
oxic and injured tissues suggestively via oxidant-mediated mech-
anisms and the up-regulation of angiogenesis-related molecules
[47]. On the other hand, it is known that the primary
angiogenesis-related gene activation mechanisms occur via acti-
vation of the hypoxia-sensor molecule HIF-1a [48]. While algae
respiration might be taking place during the dark periods to which
the scaffolds are exposed, consuming therefore oxygen just as the
animal cells, it has been also proven, that it is not the actual partial
oxygen pressure, but rather the changes of it registered by the cells,
what triggers the hypoxic pro-angiogenic transcriptional function
of HIF-1a [49]. Furthermore, the photosynthetic scaffolds stimu-
lated the formation of an extended granulation-like tissue layer
underneath the implanted scaffolds, which practically covered the
defect twoweeks after implantation (Fig. 7AeD). In this regard, it is
known that epithelialization depends on the presence of a bed of
healthy granulation tissue, which is in turn oxygen dependent [47].
All these results suggest that the presence of the algae in this
setting is promoting tissue restoration, with the photosynthetic
scaffold acting more like a bioreactor rather than a scaffold itself. If
photosynthetic scaffolds could help maintaining an adequate tissue
oxygenation, the risk of stalled wound healing or tissue loss due to
chronic hypoxia could be prevented [50].
In this work, we showed that photosynthetic biomaterials
seeded with gene modified algae can be used to deliver both oxy-
gen and recombinant factors in situ. Most of the problems associ-
ated with foreign gene expression in the microalgae, such as
inefficient DNA delivery, failing on the integration into the chro-
mosome, inadequate recognition of the promoter region and
epigenetic silencing mechanisms were successfully overcome due
to the implemented strategy for recombinant protein expression
that considered the biased codon usage, the necessary regulatory
sequences and the required targeting signals for protein secretion.
Following this system, further strains could be engineered to syn-
thesize other therapeutic proteins such as antibiotics, enzymes, or
immune-modulatory molecules, and used to create a pro-
regenerative microenvironment in the wound area. In addition,
by exploring the use of inducible promoters, gene expression by the
microalgae could be coupled to the progress of wound healing and
its requirements. Finally, because working with healthy young
animals gives an elusive reference of the approach performance,further experiments should be performed to evaluate the thera-
peutic impact of photosynthetic scaffolds in larger tissue defects or
models with impaired healing capacity.
5. Conclusion
In order to overcome hypoxia, we have previously suggested
that photosynthetic tissue engineering could be used as an alter-
native source of oxygen supply to blood vessel-perfusion. In this
work, we demonstrated that photosynthetic scaffolds can be
compatibly engrafted in fully immunocompetent mice without
causing a significant immune response and improving tissue
regeneration. In addition, we were able to genetically engineer a
C. reinhardtii strain to secrete the human growth factor VEGF, and
deliver it into a wounded tissue in vivo. The results of this work
represent a step forward in the development of autotrophic tissues,
and suggest the use of engineered microalgae to treat a broad
spectrum of hypoxic conditions as well as an alternative method for
recombinant growth factor administration in other clinical set.
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